Division of Endocrinology, Department of Pediatrics, Stanford University, Stanford, CA 94305, USA.
Endocrinol Metab Clin North Am. 2012 Dec;41(4):695-712. doi: 10.1016/j.ecl.2012.07.003.
Remarkable progress has been made in strategies to arrest pancreatic β-cell destruction in type 1 diabetes. Although knowledge of the disease has increased, a safe therapeutic intervention to reverse or prevent it remains elusive. The interaction of genes, immune system, and environment result in a complex disease process that has delayed hopes for a cure. Several well-designed prevention and intervention studies have aspired to test potentially efficacious and safe therapies. This article updates the principles used to design prevention and intervention trials, reviews clinical trials, addresses controversial issues, and provides a framework for future efforts to interdict this condition.
在阻止 1 型糖尿病中胰岛β细胞破坏的策略方面已经取得了显著进展。尽管对该疾病的认识有所增加，但仍然难以找到一种安全的治疗干预措施来逆转或预防它。基因、免疫系统和环境的相互作用导致了一种复杂的疾病过程，这延迟了治愈的希望。几项精心设计的预防和干预研究都旨在测试潜在有效和安全的治疗方法。本文更新了用于设计预防和干预试验的原则，回顾了临床试验，讨论了有争议的问题，并为未来遏制这种疾病的努力提供了框架。
